U.S. CDC to Review Various Vaccines Next Week

The U.S. Centers for Disease Control and Prevention (CDC) recently confirmed a meeting of the Advisory Committee on Immunization Practices (ACIP) will be conducted from June 26-28, 2024.

The agenda for this ACUP meeting includes discussions of new and existing vaccines, such as:

With three RSV vaccines and one monoclonal antibody approved by the U.S. FDA, people and healthcare providers are seeking CDC insights for the 2024-2025 RSV season.

Dengue - While the FDA and CDC recommend the Dengvaxia vaccine, it is not generally available in the U.S. Additionally, Takeda's Qdenga® vaccine is offered in many countries confronting severe dengue outbreaks in 2024, such as Brazil, but not the U.S.

On the second day, the ACIP will discuss updated COVID-19, influenza, and pneumococcal vaccine options.

The third day's agenda includes an additional RSV discussion regarding how best to protect infants, as well as pneumococcal and HPV vaccine updates.

This ACIP meeting, like most, is open to the public and can be viewed via a YouTube link.

Any interested person wishing to make an oral public comment during an ACIP meeting should submit a request before the meeting according to the instructions in the Federal Register Notice. 

The ACIP develops recommendations for U.S. immunizations, including the ages at which vaccines should be given, the number of doses, the time between doses, and precautions and contraindications. The ACIP's recommendations are forwarded to the CDC's Director and, if adopted, become official CDC policy.

Previously approved ACIP recommendations have been published in the CDC's Morbidity and Mortality Weekly Reports, and related presentations have been posted at the CDC link.

Contact the ACIP Secretariat with questions at [email protected].